LONESTAR Phase III Trial Finds Local Consolidative Therapy Adds No Survival Benefit After Dual Immunotherapy in Metastatic NSCLC
核心洞察
Adding local consolidative therapy after induction nivolumab plus ipilimumab did not improve overall or progression-free survival in metastatic NSCLC, including oligometastatic disease.
In 166 randomized patients, median overall survival was 52.8 months with nivolumab/ipilimumab alone versus 43.2 months with LCT plus nivolumab/ipilimumab (HR 1.14; P=.54).
Among 77 patients with oligometastatic disease, median overall survival was 75.8 months with immunotherapy alone versus 42 months with LCT plus immunotherapy.
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (搜索) (NSCLC), including those with oligometastatic disease, according to Phase III results from the LONESTAR trial presented at the International Association for the Study of Lung Cancer (搜索) (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul.
The findings challenge a treatment paradigm that had shown benefit in a different therapeutic context. Local consolidative therapy has improved outcomes in selected patients with oligometastatic NSCLC treated with chemotherapy, but its role in patients receiving immune checkpoint inhibitors has remained uncertain. The LONESTAR trial tested whether reducing residual tumor burden with radiation or surgery after dual immunotherapy could improve systemic disease control.
"Adding local consolidative therapy after induction dual checkpoint blockade was feasible, but it did not improve overall survival or progression-free survival in the overall population or among patients with oligometastatic disease," said Mehmet Altan, M.D., of MD Anderson Cancer Center in Houston, Texas.
Trial Design and Patient Population
LONESTAR was an open-label, single-center, randomized Phase III trial conducted in immunotherapy-naive patients with metastatic NSCLC. After 12 weeks of induction nivolumab plus ipilimumab, patients without progression or dose-limiting toxicity were randomized to continue nivolumab/ipilimumab alone or to receive LCT followed by nivolumab/ipilimumab. LCT consisted of radiation to at least one disease site, with surgery performed when feasible.
At the June 15, 2026 data cutoff, 166 patients had been randomized: 83 to nivolumab/ipilimumab alone and 83 to LCT followed by nivolumab/ipilimumab. Seventy-seven patients had oligometastatic disease at randomization. In the LCT arm, 16 patients underwent surgery and 71 patients received radiation to at least one disease site.
Survival Outcomes
In the overall randomized population, median overall survival was 52.8 months with nivolumab/ipilimumab alone compared with 43.2 months with LCT plus nivolumab/ipilimumab (HR 1.14; 95% CI, 0.75-1.74; P=.54). Median progression-free survival was 24.3 months versus 31.3 months, respectively (HR 0.79; 95% CI, 0.54-1.15; P=.22).
Among patients with oligometastatic disease, median overall survival was 75.8 months with nivolumab/ipilimumab alone versus 42 months with LCT plus nivolumab/ipilimumab. Median progression-free survival in this subgroup was 44.0 months versus 35.7 months, respectively.
Safety and Immunologic Observations
LCT did not increase the overall incidence of grade 3 or higher adverse events. However, pneumonitis was numerically more frequent in the LCT arm, occurring in 9.5% of patients compared with 4.9% with nivolumab/ipilimumab alone. Investigators also observed markedly lower absolute lymphocyte counts when systemic therapy was restarted in the LCT arm.
Implications for Practice
The investigators concluded that adding LCT after induction dual checkpoint blockade was feasible but did not improve overall or progression-free survival in an unselected metastatic NSCLC population, including patients with oligometastatic disease. The results stand in contrast to earlier experience with LCT in chemotherapy-treated oligometastatic disease and suggest that the strategy does not translate to patients receiving dual immune checkpoint inhibition.